Severe psoriatic arthritis patient being managed by anti IL-17A inhibition therapy in 108 Military Central Hospital

  • Vu Thi Thanh Hoa 108 Military Central Hospital
  • Bui Hoang Anh 108 Military Central Hospital
  • Nguyen Minh Son 108 Military Central Hospital
  • Tran Hong Nghi 108 Military Central Hospital

Main Article Content

Keywords

Psoriatic arthritis, Interleukin 17A inhibitor

Abstract

The article would like to introduce a psoriatic arthritis (PsA) patient in the Department of Rheumatology of 108 Military Central Hospital. This case of PsA had the secondary tuberculosis infection after Tumor necrotic factor inhibitor (TNFi) treatment, nevertheless the articular destruction caused by PsA still went on. The next management in these patients is always a controversy among the rheumatologists because the lack of international and national recommendation of management step-by-step. In addition, there were not many articles mentioning about this problem. After doctors-patient discussion, patient decided to be administered with Interleukin 17A inhibitor (IL-17Ai) (four doses secukinumab 300mg SC) plus methotrexate, then the disease remission (Minimal disease activity) was achieved without burden of tuberculosis. This success could contribute to the clinical experiences of biologic therapy in patients with severe side effects of TNFi treatment which becomes the more and more popular and causing many difficulties for clinicians.

Article Details

References

1. The 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
2. Alberto et al (2011) Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. Rhematol May 38(5): 898-903.
3. Bruce B et al (2005) Health assessment questionnaire. 23(5-39): 14-18.
4. The nation recommendation of diagnosis and treatment of rheumatoid disorders 2014. Vietnamese Ministry of Health: 59-62.
5. Dhavalkumar DP et al (2012) Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis: 1-8.
6. McInnes IB et al (2018) Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the future 2 study. Arthritis Research and Therapy 20: 113.
7. Felten R et al (2020) At the crossroads of gout and psoriatic arthritis: “psout”. Clinical Rhematol 39(5):1405-1413..
8. Nguyen Ngoc Lan Psoriatic arthritis. Textbook of musculoskeletal diseases - Post-graduation students

Article Sidebar

PDF (Tiếng Việt)
Published
Apr 1, 2021
DOI: https://doi.org/10.52389/ydls.v15iTA.736
Issue
Volume 15 - December 2020
Section
Articles
How to Cite
HoaV. T. T., AnhB. H., SonN. M., & NghiT. H. (2021). Severe psoriatic arthritis patient being managed by anti IL-17A inhibition therapy in 108 Military Central Hospital . Tạp Chí Y Dược lâm sàng 108, 15(TA). https://doi.org/10.52389/ydls.v15iTA.736